En studie for å undersøke effekten og sikkerheten til Crizanlizumab (5 mg/kg) sammenlignet med placebo hos pasienter med sigdcellesykdom i ungdom og voksne som opplever hyppige vaso-okklusive kriser (SPARKLE) (SPARKLE)
En fase III, multisenter, randomisert, placebokontrollert, dobbeltblind studie for å vurdere effektivitet og sikkerhet av Crizanlizumab (5 mg/kg) versus placebo, med eller uten hydroksyurea/hydroksykarbamidterapi, hos ungdom og voksne sigdcellepasienter med hyppig vaso - Okklusive kriser
A phase III, multi-center, randomized, placebo-controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult Sickle Cell Disease patients with frequent vaso-occlusive crises.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Study CSEG101A2303 (SPARKLE) is a Phase III, multicenter, randomized, double-blind study to assess efficacy and safety of crizanlizumab 5 mg/kg versus placebo, with or without hydroxyurea/ hydroxycarbamide therapy (HU/HC), in Sickle Cell Disease patients aged 12 years and older with frequent vaso-occlusive crises (4-12 events in 12 months prior to the screening visit).
Participants will be randomized in a 2:1 ratio to the crizanlizumab 5 mg/kg or placebo treatment arm. Central randomization will be stratified by concomitant HU/HC usage (yes/no) and region (South America, North America, and sub-Saharan Africa) at baseline.
Studietype
Registrering (Antatt)
Fase
- Fase 3
Utvidet tilgang
Kontakter og plasseringer
Studiekontakt
- Navn: Novartis Pharmaceuticals
- Telefonnummer: 1-888-669-6682
- E-post: novartis.email@novartis.com
Studer Kontakt Backup
- Navn: Novartis Pharmaceuticals
- Telefonnummer: +41613241111
Studiesteder
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasil, 41253-190
- Rekruttering
- Novartis Investigative Site
-
-
Maranhão
-
São Luís, Maranhão, Brasil, 65020-070
- Rekruttering
- Novartis Investigative Site
-
-
São Paulo
-
Campinas, São Paulo, Brasil, 13083-970
- Rekruttering
- Novartis Investigative Site
-
Ribeirão Preto, São Paulo, Brasil, 14048-900
- Rekruttering
- Novartis Investigative Site
-
Sao Jose Rio Preto, São Paulo, Brasil, 15090-000
- Rekruttering
- Novartis Investigative Site
-
São Paulo, São Paulo, Brasil, 08270-070
- Rekruttering
- Novartis Investigative Site
-
São Paulo, São Paulo, Brasil, 01232-010
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Montería, Colombia, 230001
- Rekruttering
- Novartis Investigative Site
-
-
Antioquia
-
Medellín, Antioquia, Colombia, 050001
- Rekruttering
- Novartis Investigative Site
-
-
Valle del Cauca Department
-
Cali, Valle del Cauca Department, Colombia, 760046
- Rekruttering
- Novartis Investigative Site
-
Cali, Valle del Cauca Department, Colombia, 760032
- Rekruttering
- Novartis Investigative Site
-
-
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35233
- Rekruttering
- University Of Alabama
-
Hovedetterforsker:
- Chibuzo Churchill Ilonze
-
Ta kontakt med:
- Jeanine Dumas
- Telefonnummer: +1 205 638 9285
- E-post: jdumas@uabmc.edu
-
-
California
-
Orange, California, Forente stater, 92868
- Rekruttering
- Ctr for Inherited Blood Disorders
-
Ta kontakt med:
- Emily Lopez
- E-post: elopez@cibd-ca.org
-
Hovedetterforsker:
- Vanessa Salinas
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20010
- Rekruttering
- Childrens National Hospital
-
Hovedetterforsker:
- Andrew Campbell
-
Ta kontakt med:
- Taylor Quinn
- Telefonnummer: +1 202 476 5000
- E-post: tquinn@childrensnational.org
-
-
Florida
-
Jacksonville, Florida, Forente stater, 32209
- Rekruttering
- University of Florida
-
Hovedetterforsker:
- Gabriela Bastidas
-
Ta kontakt med:
- Tatiana Elias-Grajeda
- E-post: tatiana.elias-grajeda@jax.ufl.edu
-
-
Georgia
-
Augusta, Georgia, Forente stater, 30912
- Rekruttering
- Augusta University Georgia
-
Hovedetterforsker:
- Girindra Raval
-
Ta kontakt med:
- Latanya Bowman
- Telefonnummer: +1 706 721 2941
- E-post: lbowman@augusta.edu
-
Riverdale, Georgia, Forente stater, 30274
- Rekruttering
- WCG Sonar Clinical Research
-
Hovedetterforsker:
- Anthony Onyegbula
-
Ta kontakt med:
- Ify Anierobi
- E-post: ianierobi@sonarcr.com
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60612
- Rekruttering
- Uni of Illinois Hospital and HSC
-
Ta kontakt med:
- Taif Hassan
- E-post: tohassan@uic.edu
-
Hovedetterforsker:
- Santosh Saraf
-
-
Kentucky
-
Louisville, Kentucky, Forente stater, 40202
- Rekruttering
- Norton Children s Hospital
-
Hovedetterforsker:
- Ashok Raj
-
Ta kontakt med:
- Meagan Despain
- E-post: meagan.despain@louisville.edu
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21205
- Rekruttering
- The Johns Hopkins University School of Medicine
-
Hovedetterforsker:
- Lydia Pecker
-
Ta kontakt med:
- Goodness Che
- Telefonnummer: +1 410 955 2812
- E-post: anchang1@jhmi.edu
-
-
Mississippi
-
Flowood, Mississippi, Forente stater, 39232
- Rekruttering
- Southern Specialty Research
-
Hovedetterforsker:
- Sharon Pennington
-
Ta kontakt med:
- Wendy Thomson
- E-post: wendy.thomson@southernspecialty.org
-
-
New York
-
The Bronx, New York, Forente stater, 10467
- Rekruttering
- Childrens Hospital at Montefiore
-
Hovedetterforsker:
- Kaitlin Strumph
-
Ta kontakt med:
- Karen Ireland
- Telefonnummer: +1 718 741 2384
- E-post: kireland@montefiore.org
-
-
North Carolina
-
Greenville, North Carolina, Forente stater, 27834
- Rekruttering
- East Carolina University
-
Hovedetterforsker:
- Beng Fuh
-
Ta kontakt med:
- Tori Donadio
- E-post: donadiov21@ecu.edu
-
Winston-Salem, North Carolina, Forente stater, 27157
- Rekruttering
- Wake Forest University Baptist Medical Center
-
Ta kontakt med:
- Julie Fountain
- E-post: julie.fountain@advocatehealth.org
-
Hovedetterforsker:
- Alex George
-
-
Pennsylvania
-
Easton, Pennsylvania, Forente stater, 18045
- Rekruttering
- Spoknwrdclinicaltrials
-
Hovedetterforsker:
- Hayman Salib
-
Ta kontakt med:
- Anne Murunga
- E-post: amurunga@spoknwrdclinicaltrials.com
-
Philadelphia, Pennsylvania, Forente stater, 19107
- Rekruttering
- Thomas Jefferson University Me
-
Ta kontakt med:
- Katie McDonnell
- E-post: Katie.McDonnell@jefferson.edu
-
Hovedetterforsker:
- Sanaa Rizk
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- U of TX Health Science Ct
-
Hovedetterforsker:
- Modupe Idowu
-
Ta kontakt med:
- Eyuel Baherey
- E-post: Eyuel.L.Baherey@uth.tmc.edu
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- Texas Childrens Cancer and Hematology Center
-
Hovedetterforsker:
- Venee Tubman
-
Ta kontakt med:
- Bogdan Dinu
- Telefonnummer: +1 832 824 1000
- E-post: brdinu@texaschildrens.org
-
-
-
-
-
Eldoret, Kenya, 30100
- Rekruttering
- Novartis Investigative Site
-
Kisumu, Kenya, 40100
- Rekruttering
- Novartis Investigative Site
-
Kisumu, Kenya, 40103
- Rekruttering
- Novartis Investigative Site
-
Siaya, Kenya, 40600
- Rekruttering
- Novartis Investigative Site
-
-
Kisumu County
-
Ahero, Kisumu County, Kenya, 40100
- Rekruttering
- Novartis Investigative Site
-
-
-
-
-
Kampala, Uganda, 101
- Rekruttering
- Novartis Investigative Site
-
Masaka, Uganda, 001
- Rekruttering
- Novartis Investigative Site
-
Tororo, Uganda, 10102
- Rekruttering
- Novartis Investigative Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
- Participants must be aged 12 years and older on the day of signing informed consent. Adolescents include participants aged 12 to <18 years old and adults include participants aged 18 years and older.
- Confirmed diagnosis of SCD by Hb electrophoresis or high-performance liquid chromatography (HPLC) (performed locally or by central laboratory if not available locally). All SCD genotypes are eligible.
- Experienced 4 to 12 VOCs (refer to Section 8.3.1 for study definition of VOC) that are HCP-managed (including VOCs leading to management at a health care facility or those managed via remote consultation) within the 12 months prior to the screening visit. Baseline VOCs are determined by medical history and are required to be documented at source.
- If the participant is on HU/HC, they must be taking it for at least 6 months and at stable dose for at least 3 months prior to the Screening visit and plan to continue taking it at the same dose and schedule until at least the participant has reached 52 weeks of the planned study treatment. Participants who have initiated HU/HC 6-12 months prior to the screening visit must have evidence of insufficient control of acute pain despite initiation. These participants must have a cumulative of 4-12 VOCs in the 12 months prior to the screening period, with at least 2 during the last 6 months while on HU/HC. If receiving erythropoietin stimulating agent, the participant must have been receiving the drug for at least 6 months prior to screening visit and plan to continue taking the drug at the same dose and schedule until the participant has reached 52 weeks of the planned study treatment.
Participants who have not been receiving HU/HC, and/or erythropoietin stimulating agent must not have received it for at least 6 months prior to screening visit.
Key Exclusion Criteria:
- Fewer than 4 or more than 12 VOCs that are HCP-managed (including VOCs leading to management at a health care facility or those managed via remote consultation) within the 12 months prior to screening visit as determined by medical history and documented at source.
- History of stem cell transplant and/or gene therapy.
- Received blood products within 30 days prior to Week 1 Day 1 dosing.
- Any documented history of a clinical stroke or intracranial hemorrhage, or an uninvestigated neurologic finding within the past 12 months before screening visit. Silent infarct only present on imaging is not excluded.
- Participating in a chronic transfusion program (pre-planned series of transfusions for prophylactic purposes) and/or planning to undergo an exchange transfusion during the duration of the study; episodic transfusion in response to worsened anemia or VOC is permitted.
- Contraindication or hypersensitivity to any drug or metabolites from similar class as study drug or to any excipients of the study drug formulation. History of severe hypersensitivity reaction to other monoclonal antibodies, which in the opinion of the investigator may pose an increased risk of serious infusion reaction.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Crizanlizumab (SEG101) at 5.0 mg/kg
Participants receive Crizanlizumab (SEG101) at 5.0 mg/kg and standard of care. |
Crizanlizumab is supplied in single use 10 mL glass vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab. This is a concentrate for solution for IV infusion.
Andre navn:
|
|
Placebo komparator: Placebo
Participants receive the placebo drug and standard of care. |
Placebo is supplied in single use 10 mL glass vials at a concentration of 0 mg/mL. This is a concentrate for solution for IV infusion. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Annualized rate of VOCs that are healthcare professional (HCP)-managed (including VOCs leading to management at a health care facility or those managed via remote consultation) in each treatment arm
Tidsramme: 1 year
|
Vaso oclusive crisis (VOC) is defined as a pain crisis (acute onset of pain for which there is no other medically determined explanation other than vaso-occlusion) lasting for at least 4 hours which is treated as per local guidelines with standard of care therapy used to treat VOC. Acute chest syndrome (ACS), priapism and hepatic or splenic sequestration will be considered VOC in this study. VOCs included are those HCP-managed in a healthcare facility and HCP-managed via remote consultation. Annualized rate of VOC events = (Number of VOC events * 365)/(number of days in the observation period). Observation period = time from date of randomization to minimum of (last dose date until treatment discontinuation + 27 days, date of initiation or discontinuation of HU/HC or L-Glutamine (or other therapies such as Voxelotor and erythropoietin therapies to treat SCD and/or to prevent/reduce VOCs), date of randomization + 365 days). |
1 year
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The annualized rate of all VOCs including VOCs that are HCP-managed (either at a health care facility or via remote consultation) as well as those that are self-managed without recommendations from HCP during the event in each treatment arm
Tidsramme: 1 year
|
VOCs can be categorized as those HCP-managed in a healthcare facility, HCP-managed via remote consultation, or self-managed without recommendations from HCP during the event. Annualized rate of VOC events = (Number of VOC events * 365)/(number of days in the observation period). To capture VOC events that are self-managed, and in order to avoid VOC recall bias and to make sure the pain events are captured in real-time, a cloud-based application will be used and setup an account for each participant. |
1 year
|
|
Annualized rate of VOC by subtype of management in each treatment arm over the planned 52-week period.
Tidsramme: 1 year
|
Vaso oclusive crisis (VOC) is defined as a pain crisis lasting for at least 4 hours which is treated as per local guidelines with standard of care therapy. Acute chest syndrome (ACS), priapism and hepatic or splenic sequestration will be considered VOC in this study. VOCs can be categorized as those HCP-managed in a healthcare facility, HCP-managed via remote consultation, or self-managed without recommendations from HCP during the event. Annualized rate of VOC is the number of VOC events during a year period. |
1 year
|
|
The time to first VOC that is HCP-managed (including VOCs leading to management at a health care facility or those managed via remote consultation) between treatment arms.
Tidsramme: 1 year
|
VOC is defined as a pain crisis lasting for at least 4 hours which is treated as per local guidelines with standard of care therapy. ACS, priapism and hepatic or splenic sequestration will be considered VOC in this study. VOCs included are those HCP-managed in a healthcare facility and HCP-managed via remote consultation. Time to first occurrence of VOC that is HCP-managed (either at a health care facility or via remote consultation) is defined as the time from the date of randomization to the date of the first occurrence of the VOC. |
1 year
|
|
Proportion of participants free from VOCs that are HCP-managed (including VOCs leading to management at a health care facility or those managed via remote consultation) in each treatment arm over the planned 52-week treatment period.
Tidsramme: 1 year
|
To assess the number of participants free from VOCs leading to healthcare visit. VOC is defined as a pain crisis lasting for at least 4 hours which is treated as per local guidelines with standard of care therapy. ACS, priapism and hepatic or splenic sequestration will be considered VOC in this study. A participant is free from VOC if they do not have a VOC crisis. |
1 year
|
|
Duration of VOCs that are HCP-managed (including VOCs leading to management at a health care facility or those managed via remote consultation) in each treatment arm over the planned 52-week treatment period.
Tidsramme: 1 year
|
VOC is defined as a pain crisis lasting for at least 4 hours which is treated as per local guidelines with standard of care therapy. ACS, priapism and hepatic or splenic sequestration will be considered VOC in this study. Duration of HCP-managed VOC is defined as end date of the VOC - start date of the VOC + 1 day. |
1 year
|
|
Number of participants with anti-SEG101 (crizanlizumab) antibodies (any time)
Tidsramme: 2 years
|
Immunogenicity: measurement of anti-drug antibodies (ADA) to crizanlizumab. |
2 years
|
|
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsramme: 2 years
|
Incidence and severity of AEs and SAEs by treatment group, including changes in vital signs, electrocardiograms (ECGs), and laboratory results qualifying and reported as AEs. |
2 years
|
|
Absolute change from baseline in hemoglobin
Tidsramme: Baseline, 2 years
|
Assessment of safety of SEG101 |
Baseline, 2 years
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CSEG101A2303
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .